April Global News
The Drugs for Neglected Diseases initiative (DNDi; Geneva, Switzerland) received ?5 million from Spain's Agencia Espa?ola de Cooperaci?n Internacional, based in Madrid, to aid in the research and development of new, effective, and affordable drugs for neglected diseases, including Chagas disease, human African trypanosomiasis, and malaria. DNDi plans to develop two new malaria drugs by the end of the year and is looking to create between six and eight new drugs for neglected diseases by 2014.
April Global News
• The Drugs for Neglected Diseases initiative (DNDi; Geneva, Switzerland) received €5 million from Spain's Agencia Española de Cooperación Internacional, based in Madrid, to aid in the research and development of new, effective, and affordable drugs for neglected diseases, including Chagas disease, human African trypanosomiasis, and malaria. DNDi plans to develop two new malaria drugs by the end of the year and is looking to create between six and eight new drugs for neglected diseases by 2014.
• Thailand's Public Health Minister Chaiya Sasomsap announced that Siriwat Thiptharadon, head of Thailand's Food and Drug Administration, was removed from his position and moved instead to an inactive post. Thiptharadon is known for establishing the former government's compulsory license program, which aimed to make drugs more affordable and is now vulnerable to a committee review under Sasomsap's orders. Chatree Banchuen was named secretary general of Thailand's FDA following Thiptharadon's departure, but resigned a week later citing that he was "uncomfortable with the politics."
• Kampala, Uganda's Mulago Hospital, a 1500-bed facility affiliated with Makerere University, is the home of the first Health Volunteers Overseas (HVO; Washington, DC) hematology training program, created by HVO and the American Society of Hematology (Washington, DC). The program's purpose is to bolster the hematology training of clinicians, lab technicians, technologists, and students.
• The University of Portsmouth (Hampshire, UK) is collaborating with brain tumor charity Brainstrust (Hampshire, UK) among others to create the UK's first dedicated laboratory-based brain tumor research center. Brain tumors are the most common form of cancer in people under 40 and the most common cause of death in children after accidents.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Full Phase IIIb BATURA Trial Results Show Airsupra Cuts Severe Exacerbations by 47% in Mild Asthma
May 20th 2025Results from the pivotal BATURA trial show that Airsupra (albuterol/budesonide) significantly outperformed albuterol monotherapy in reducing severe asthma exacerbations and systemic corticosteroid exposure, reinforcing its role as a next-generation, anti-inflammatory rescue therapy for mild asthma patients.
